ICB BIOTECHNOLOGY (Israel) Performance

The corporation owns Beta (Systematic Risk) of 0.0 which attests that the returns on MARKET and ICB BIOTECHNOLOGY are completely uncorrelated. Although it is extremely important to respect ICB BIOTECHNOLOGY existing price patterns, it is better to be realistic regarding the information on equity price patterns. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By evaluating ICB BIOTECHNOLOGY technical indicators you can at this time evaluate if the expected return of 0.0% will be sustainable into the future. ICB BIOTECHNOLOGY at this moment owns a risk of 0.0%. Please check out ICB BIOTECHNOLOGY Downside Deviation, Treynor Ratio, Expected Short fall, as well as the relationship between Variance and Potential Upside to decide if ICB BIOTECHNOLOGY will be following its current price history.

Risk-Adjusted Performance

Over the last 30 days ICB BIOTECHNOLOGY has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, ICB BIOTECHNOLOGY is not utilizing all of its potentials. The current stock price disturbance, may contribute to short term losses for the investors.
Horizon     30 Days    Login   to change

ICB BIOTECHNOLOGY Relative Risk vs. Return Landscape

If you would invest  0.00  in ICB BIOTECHNOLOGY on December 24, 2019 and sell it today you would earn a total of  0.00  from holding ICB BIOTECHNOLOGY or generate 0.0% return on investment over 30 days. ICB BIOTECHNOLOGY is producing return of less than zero assuming 0.0% volatility of returns over the 30 days investment horizon. Simply put, 0% of all equities have less volatile historical return distribution than ICB BIOTECHNOLOGY and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
  Risk (%) 

ICB BIOTECHNOLOGY Market Risk Analysis

Sharpe Ratio = 0.0
Good Returns
Average Returns
Small Returns
Based on monthly moving average ICB BIOTECHNOLOGY is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ICB BIOTECHNOLOGY by adding it to a well-diversified portfolio.


Equity Alerts and Improvement Suggestions

ICB BIOTECHNOLOGY is not yet fully synchronised with the market data
ICB BIOTECHNOLOGY has some characteristics of a very speculative penny stock
See also Risk vs Return Analysis. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Company logos by clearbit